FARAPULSE s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation
News provided by
Share this article
Share this article
Pioneering technology has demonstrated potential to improve safety for patients with paroxysmal atrial fibrillation and simplify procedures for physicians
MENLO PARK, Calif., March 3, 2021 /PRNewswire/ - FARAPULSE Inc. today announced the first patients were treated in the
ADVENT Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal Atrial Fibrillation (AF). AF is a heart rhythm disorder that affects nearly 6 million Americans and makes them five times more likely to have a stroke than individuals with a regular heartbeat. The first patients were treated at New York s Mount Sinai Hospital by Dr. Vivek Reddy, the Hel
First AF Patients Treated With Farapulse Pulsed Field Ablation System
Pioneering technology may simplify procedures and improve outcomes for patients with paroxysmal atrial fibrillation
March 3, 2021 Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial to evaluate the safety and effectiveness of its Pulsed Field Ablation (PFA) system for the treatment of paroxysmal atrial fibrillation (AF).
The first patients were treated at New York s Mount Sinai Hospital by Vivek Reddy, M.D., the Helmsley Trust Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the trial s principal investigator.